Aurinia Pharmaceuticals Inc. (AUPH) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Aurinia Pharmaceuticals Inc. (AUPH) trades at $15.24 with AI Score 57/100 (Grade B). Aurinia Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing therapies for unmet medical needs, particularly in lupus nephritis. Market cap: $1.96B, Sector: Healthcare.
Price as of Jul 23, 2026 · Last analyzed: May 10, 2026AUPH stock analysis for 2026: Analysts have set a consensus price target of $17.00 for Aurinia Pharmaceuticals Inc., suggesting 11.5% upside from the current price of $15.24. The AI MoonshotScore is 57/100, indicating a neutral outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
AUPH: 2/3 scored disciplines lean bullish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Aurinia Pharmaceuticals Inc. (AUPH) Healthcare & Pipeline Overview
Aurinia Pharmaceuticals Inc. is a leading biopharmaceutical company dedicated to addressing unmet medical needs through innovative therapies, notably its flagship product LUPKYNIS, which targets lupus nephritis and showcases strong market potential.
What Is the Investment Thesis for AUPH?
Aurinia Pharmaceuticals Inc. presents a compelling investment thesis driven by its flagship product, LUPKYNIS, which addresses a significant unmet need in the treatment of lupus nephritis. With a market capitalization of $1.96B and a P/E ratio of 6.8, the company is positioned favorably compared to industry peers. The ongoing collaboration with Otsuka Pharmaceutical Co., Ltd. is expected to enhance market penetration and revenue growth, particularly as the global lupus nephritis market is projected to grow significantly in the coming years. Additionally, Aurinia's impressive profit margin of 100% indicates strong operational efficiency. Key risks include potential regulatory hurdles and competition from alternative therapies, which could impact market share and revenue growth. However, the company's focus on innovation and strategic partnerships provides a solid foundation for future growth.
Based on FMP financials and quantitative analysis
AUPH Key Highlights
- Market Cap of $1.96B indicates strong market presence in the biotechnology sector.
- P/E ratio of 6.8 suggests attractive valuation compared to industry peers.
- Profit margin of 100% reflects exceptional operational efficiency and profitability.
- Gross margin of 89.7% exceeds industry averages, highlighting strong pricing power.
- Beta of 1.59 indicates higher volatility compared to the market, suggesting potential for significant price movements.
Who Are AUPH's Competitors?
AUPH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNY Sanofi | $43.36 | -0.98% | $105B | 58 |
| ABBV AbbVie Inc. | $255.25 | +0.77% | $451B | 80 |
| BMY Bristol-Myers Squibb Company | $61.65 | +1.46% | $126B | 90 |
| ADMA ADMA Biologics, Inc. | $8.29 | -1.01% | $1.92B | 90 |
| HRMY Harmony Biosciences Holdings, Inc. | $35.80 | +2.70% | $2.07B | 98 |
| GLPG Galapagos NV | $27.98 | +1.71% | $1.84B | 70 |
| MBX MBX Biosciences | $63.57 | +9.04% | $2.14B | 75 |
| ABCL AbCellera Biologics Inc. | $5.67 | -1.05% | $1.73B | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AUPH's Key Strengths?
- Strong product offering with LUPKYNIS addressing a critical need.
- High profit and gross margins demonstrating financial health.
- Strategic partnership with Otsuka enhances market access.
What Are AUPH's Weaknesses?
- Limited product portfolio focused primarily on lupus nephritis.
- Dependence on a single product for revenue generation.
- Relatively small workforce may limit operational scalability.
What Could Drive AUPH Stock Higher?
- Expansion of LUPKYNIS into new international markets expected to drive revenue growth.
- Collaboration with Otsuka Pharmaceutical Co., Ltd. enhancing distribution capabilities.
- Potential new indications for LUPKYNIS could diversify revenue streams.
What Are the Key Risks for AUPH?
- Regulatory hurdles could delay product approvals and market entry.
- Competition from other biopharmaceutical companies in the autoimmune space.
- Market volatility may impact stock performance and investor sentiment.
What Are the Growth Opportunities for AUPH?
- Growth opportunity 1: The global lupus nephritis market is projected to reach $5 billion by 2027, driven by increasing prevalence and awareness. Aurinia's LUPKYNIS, being one of the few approved treatments, positions the company to capture a significant share of this expanding market over the next five years.
- Growth opportunity 2: Aurinia's collaboration with Otsuka Pharmaceutical Co., Ltd. enhances its distribution capabilities, allowing for broader market access and increased sales potential. This partnership is expected to accelerate market penetration and revenue growth, particularly in regions with high unmet needs.
- Growth opportunity 3: The company is exploring additional indications for LUPKYNIS beyond lupus nephritis, which could diversify its product portfolio and open new revenue streams. If successful, this could significantly enhance the company’s market position and financial performance.
- Growth opportunity 4: Continued investment in R&D could lead to the development of new therapies targeting other autoimmune diseases. With a focus on unmet medical needs, Aurinia has the potential to expand its therapeutic offerings and strengthen its market presence.
- Growth opportunity 5: Increasing collaborations and partnerships within the biotechnology sector can enhance Aurinia's research capabilities and accelerate the development of new products. This strategy could position the company for sustained growth and innovation in the competitive landscape.
What Opportunities Does AUPH Have?
- Expanding global lupus nephritis market presents growth potential.
- Possibility of developing new indications for existing therapies.
- Increased collaboration opportunities within the biotechnology sector.
What Threats Does AUPH Face?
- Potential regulatory challenges affecting product approvals.
- Competition from established pharmaceutical companies.
- Market volatility could impact stock performance.
What Are AUPH's Competitive Advantages?
- Strong intellectual property protection for LUPKYNIS.
- Established partnerships with major pharmaceutical companies like Otsuka.
- Focused expertise in lupus nephritis, providing a competitive advantage.
- High profit margins indicating operational efficiency.
- Limited competition in the specific treatment area of lupus nephritis.
What Does AUPH Do?
Founded in 2013 and headquartered in Victoria, Canada, Aurinia Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company that specializes in developing and commercializing therapies for diseases with significant unmet medical needs. The company has made substantial strides in the biotechnology sector, particularly with its primary product, LUPKYNIS (voclosporin), which is designed for the treatment of adult patients suffering from active lupus nephritis. This condition, characterized by inflammation of the kidneys due to lupus, presents a significant challenge in patient management and has limited treatment options. Aurinia's commitment to addressing this gap in the market has positioned it as a key player in the healthcare landscape. The company has also established a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd., enhancing its commercial capabilities and market reach. With a workforce of approximately 130 employees, Aurinia is focused on expanding its product offerings and improving patient outcomes through innovative therapies. The company's strategic focus on unmet medical needs, combined with its strong financial metrics, including a profit margin of 100% and a gross margin of 89.7%, underscores its potential for growth and sustainability in the competitive biopharmaceutical market.
What Products and Services Does AUPH Offer?
- Develops and commercializes therapies for diseases with unmet medical needs.
- Offers LUPKYNIS, a treatment for adult patients with active lupus nephritis.
- Engages in collaborations with other pharmaceutical companies to enhance market reach.
- Focuses on innovative solutions in the biopharmaceutical space.
- Operates primarily in the United States and internationally.
- Aims to improve patient outcomes through targeted therapies.
How Does AUPH Make Money?
- Generates revenue primarily through the sale of LUPKYNIS.
- Engages in strategic partnerships to enhance distribution and market access.
- Invests in R&D to develop new therapies and expand product offerings.
- Utilizes licensing agreements to monetize its innovations.
- Focuses on addressing unmet medical needs to drive demand for its products.
What Industry Does AUPH Operate In?
The biotechnology industry is experiencing robust growth, driven by advancements in medical research and increasing demand for innovative therapies. The global lupus nephritis market is anticipated to expand significantly, fueled by rising awareness and diagnosis rates. Aurinia Pharmaceuticals Inc. is well-positioned within this landscape, leveraging its specialized focus on lupus nephritis to capture market share. The competitive landscape includes several established players, but Aurinia's unique product offering and strategic partnerships provide a competitive edge.
Who Are AUPH's Key Customers?
- Healthcare providers and hospitals treating lupus nephritis patients.
- Pharmaceutical distributors and wholesalers.
- Patients seeking effective treatments for lupus nephritis.
- Insurance companies covering treatments for autoimmune diseases.
- Research institutions collaborating on clinical trials.
Company Profile
Aurinia Pharmaceuticals Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Edmonton, CA. The company is led by CEO Kevin C. Tang. AUPH has traded publicly since 2014.
ROE 64%Key Financial Metrics
Return on equity for Aurinia Pharmaceuticals Inc. stands at 64.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 41.2%, showing how much profit it generates from its asset base. AUPH trades at a trailing price-to-earnings ratio of 6.80, below the Healthcare sector average of ~23x. Its free cash flow yield is 8.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.55 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 14.4%, the inverse of the P/E and a quick read on earnings relative to price.
AUPH Valuation & Market Position
With a $1.96B market cap, Aurinia Pharmaceuticals Inc. sits in the small-cap segment of the market. Relative to its peer group, AUPH's quantitative score of 57/100 is below the peer average of 83/100.
Quarterly Financial Performance: Aurinia Pharmaceuticals Inc.
Revenue for Aurinia Pharmaceuticals Inc. came in at $77.7M during Q1 2026. The company recorded net income of $34.4M, with diluted EPS of $0.25. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this small-cap Healthcare company. Across the four most recent quarters, AUPH averaged $0.54 in diluted EPS.
F-Score 6/9Financial Health
Aurinia Pharmaceuticals Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 8.09 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project Aurinia Pharmaceuticals Inc. revenue of about $326.4M for fiscal 2026, with EPS near $0.96. The estimate reflects 5 contributing analysts.
AUPH Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying indicates strong confidence in Aurinia's future prospects, suggesting insiders believe the stock is undervalued.
- Community sentiment has shown a growing optimism surrounding Aurinia's pipeline, particularly its lead drug, which has garnered positive feedback in recent discussions.
- Market perception has shifted positively due to recent collaborations that enhance the company's research capabilities and market reach.
- Analysts and social sentiment reflect an increasing belief in the potential for regulatory approvals, which could significantly boost the company's standing.
Bear Case
- Despite some positive sentiment, there remains skepticism about the long-term viability of Aurinia's lead drug, with some community members questioning its market potential.
- Recent discussions highlight concerns over the company's cash burn rate, raising doubts about its ability to sustain operations without additional funding.
- Insider selling activity has raised red flags for some investors, indicating a lack of confidence among certain stakeholders about the near-term outlook.
- The overall market sentiment is cautious, with broader economic factors causing apprehension about biotech stocks, including Aurinia.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $78M | $34M | $0.25 |
| Q4 2025 | $77M | $211M | $1.53 |
| Q3 2025 | $73M | $32M | $0.23 |
| Q2 2025 | $70M | $22M | $0.15 |
Based on FMP financials and quantitative analysis
AUPH Latest News
-
Sector Update: Healthcare Stocks Fall Monday Afternoon
MT Newswires · Jul 6, 2026
-
Health Care Roundup: Market Talk
The Wall Street Journal · Jun 9, 2026
-
10 Health Care Stocks Whale Activity In Today's Session
benzinga · Jun 5, 2026
-
Earnings Scheduled For February 26, 2026
benzinga · Feb 26, 2026
AUPH Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AUPH.
Price Targets
Consensus target: $17.00
AUPH MoonshotScore
What does this score mean?
The MoonshotScore rates AUPH 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Latest News
Leadership: Peter S. Greenleaf
CEO
Peter S. Greenleaf has extensive experience in the pharmaceutical industry, having held various leadership roles in both public and private companies. He has a proven track record in driving growth and operational excellence, with a focus on innovative therapies. Greenleaf holds a degree in Business Administration and has been instrumental in shaping Aurinia's strategic direction since joining the company.
Track Record: Under Greenleaf's leadership, Aurinia has successfully launched LUPKYNIS and established a strong market presence. His strategic decisions have positioned the company for future growth, particularly through partnerships and product development initiatives.
AUPH Healthcare Stock FAQ
What does the AI Score mean for AUPH?
AUPH holds an AI Score of 57/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Aurinia Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing therapies for unmet medical needs, particularly in lupus nephritis. The company's flagship …
What does Aurinia Pharmaceuticals Inc. do?
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that develops and commercializes therapies for diseases with unmet medical needs, particularly focusing on lupus nephritis. Its primary product, LUPKYNIS, is designed to treat adult patients with this condition, providing a critical treatment option in a market with limited alternatives.
What do analysts say about AUPH stock?
Analysts generally view AUPH stock as an intriguing option within the biotechnology sector, particularly due to its strong financial metrics and market potential for LUPKYNIS. Key valuation metrics, including a P/E ratio of 6.8, suggest that the stock may be undervalued compared to peers, while growth considerations focus on the expanding lupus nephritis market.
What are the main risks for AUPH?
Aurinia Pharmaceuticals Inc. faces several risks, including potential regulatory challenges that could impact product approvals and market entry. Additionally, competition from established pharmaceutical companies poses a threat to market share, while overall market volatility could affect stock performance and investor confidence.
What are the key factors to evaluate for AUPH?
Aurinia Pharmaceuticals Inc. (AUPH) holds an AI score of 57/100 (moderate). P/E: 6.8x vs the S&P 500's ~20-25x. Analysts target $17.00 (+12%). Not financial advice.
How frequently does AUPH data refresh on this page?
AUPH's price was last updated on Jul 23, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven AUPH's recent stock price performance?
Aurinia Pharmaceuticals Inc. (AUPH) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong product offering with LUPKYNIS addressing a critical need. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider AUPH overvalued or undervalued right now?
Aurinia Pharmaceuticals Inc. (AUPH) trades at 6.8x earnings. Analysts target $17.00 (+12%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research AUPH before investing?
Before investing in Aurinia Pharmaceuticals Inc. (AUPH), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data sourced from company profile, financial metrics, and existing insights.